

NCIC CLINICAL TRIALS GROUP

GENITOURINARY

DISEASE SITE COMMITTEE MEETING AGENDA

CHELSEA HOTEL, TORONTO, ON

ROOM: WREN

SATURDAY MAY 2RD, 2015: 10:00 AM – 3:45 PM

CHAIRS: K. CHI & N. FLESHNER
SENIOR INVESTIGATOR: WENDY PARULEKAR
STUDY COORDINATOR: ALEXANDER MONTENEGRO

(03:45 PM – 04:15 PM EXECUTIVE COMMITTEE MEETING – CLOSED)

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To understand and address, through clinical and translational research, the disease burden associated with genitourinary malignancies in Canada.
 - To review recent developments in the understanding of molecular biology and new therapeutics as these relate to genitourinary malignancies.
 - To update, review, and discuss recent results of clinical studies conducted by or in collaboration with NCIC Clinical Trials Group.
 - To provide mentoring opportunities for investigators new to clinical trial research.
 - To understand and apply new clinical trial methodologies in the field of clinical research related to genitourinary malignancies.
-

10:00 am WELCOME

K. Chi/N. Fleshner

NCIC CTG Lead OPEN TRIALS

10:05 am IND.209 Reolysin in combination with docetaxel and prednisone
or docetaxel and prednisone alone in metastatic CRPC

B. Eigel

10:15 am BL.12 Phase II Randomized trial of Nab-Paclitaxel vs. Paclitaxel
in Second Line Metastatic Urothelial Carcinoma

K. Sridhar

10:25 am PR.15 HDR Brachytherapy in Intermediate
Risk CaP

E. Vigneault/ A. Loblaw

NCIC CTG InterGroup OPEN TRIALS

10:35 am BLC.1/SWOG S1011 Phase III Surgical Trial to Evaluate the Benefit of a
Standard versus an Extended Pelvic Lymphadenectomy Performed
at the Time Of Radical Cystectomy For Muscle Invasive Urothelial Cancer

W. Kassouf

continued on next page ...

10:45 am PR.13/RADICALS/MRC PR.10 C. Catton
Radiotherapy and Androgen Deprivation In Combination After Local Surgery.

10:55 am PRC.3/CALGB 90203 Neoadjuvant Docetaxel plus Androgen K.Chi
Deprivation prior to RP v.s. RP only *on behalf of* M. Gleave/F. Saad

11:05 am PRC.4/Alliance A031201 Phase III Enzalutamide + Abiraterone in castration K.Chi
resistant metastatic prostate cancer

11:15 am PR.17/ANZUP - ENZAMET Phase III testosterone suppression with or S. North
without Enzalutamide in first line metastatic prostate cancer

NCIC CTG InterGroup CLOSED TRIALS

11:25 am BL.8/EORTC 30994 Randomized phase III comparing K.Chi
immediate vs. deferred chemotherapy after radical *on behalf of* L. Wood//F. Saad
cystectomy in patients with pT3-pT4, and/or N+M0
transitional cell carcinoma (TCC) of the bladder

11:30 am REC.2/ECOG E2805 Sunitinib/placebo vs. M. Jewett/ L. Wood
Sorafenib/placebo vs. placebo in resected RCC

11:35 am OPEN CUOG/CURC TRIALS

Affinity	K.Chi
Synergy	K.Chi
IAS + Dutasteride	L. Klotz
EORTC Cytoreductive	M. Jewett
FIT	L. Klotz
ProstVac	N.Fleshner
Hypothermia RCC	I. Cagiannos

12:00 pm LUNCH

1:30 pm Plenary Presentation: *Designing trials to improve the care J. de Bono*
of patients with advanced prostate cancer.
[Dr. de Bono biography](#)

2:10 pm DOG REPORTS/NEW PROPOSALS/GU DIRECTIONS

Localized Prostate Cancer	A. Loblaw/N. Fleshner
Advanced Prostate Cancer	K. Chi
Bladder	S. North/W. Kassouf/A. So
Kidney	A. Kapoor
Testes	P. Chung
Correlative Studies	R. Bristow

3:45 pm Meeting Adjourned

3:45 PM – 4:15 PM EXECUTIVE COMMITTEE MEETING – CLOSED